Novo Nordisk has launched Victoza (liraglutide [rDNA origin] injection), a once-daily human glucagon-like peptide-1 (GLP-1) analog, as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. Victoza can be used as monotherapy as well as in combination with other oral anti-diabetic medications.

Victoza is available as a pre-filled, multidose pen that delivers doses of 0.6mg, 1.2mg, or 1.8mg (6mg/mL, 3mL).

For more information call (877) 4VICTOZA or visit